BioMed Research International

Drug-Induced Liver Injury


Status
Published

Lead Editor

1National Center for Toxicological Research, Jefferson, USA

2Hannover Medical School, Hannover, Germany

3University of Arkansas for Medical Sciences, Little Rock, USA

4Center for Drug Evaluation and Research, Silver Spring, USA


Drug-Induced Liver Injury

Description

Drug-induced liver injury (DILI) is a major concern in medical practice, although infrequently it can lead to serious clinical outcomes including acute liver failure (ALF). In the US, DILI accounts for over 60% of all ALF cases and it is a major reason for high urgency liver transplantation. Importantly, over 1,000 marketed drugs, herbs, and dietary supplements have been shown to carry the potential to cause liver injury and it is a common cause for termination of drug development and drug withdrawal from the market. In the past half century, DILI has resulted in over 50 approved drugs to be either withdrawn from the market or the focus of regulatory actions including the addition of boxed warnings and other product labeling modifications.

In the upcoming special issue, we invite investigators to contribute original research articles as well as review articles that seek to address a better understanding of DILI mechanisms by considering physicochemical and toxicological properties associated with individual drugs as well as complementary alternative medicines and dietary supplements. We encourage submissions dealing with various host factors that lead to idiosyncratic toxicity and contribute to an individuals’ DILI risk. Special attention will be given to papers exploring the interactions between drug properties and host factors and their relevance to DILI outcome. We also emphatically invite submissions addressing basic and clinical research on fatty liver disease and its links to risk for DILI.

Potential topics include, but are not limited to:

  • Toxicological studies
    • DILI mechanism studies for specific drugs/drug classes
    • In vitro/in vivo models such as iPSC-derived hepatocytes, 3D cell culture, humanized liver, and zebrafish
    • Toxicogenomic studies using microarray, next-generation sequencing (NGS), and microRNA expression profiles as part of Adverse Outcome Pathway (AOP) studies
    • Genetic and nongenetic biomarkers
    • Hepatotoxicity of nanomaterials
    • Bioinformatics methodologies for developing predictive models
  • Regulatory science
    • DILI issues encountered in the IND, NDA, or pharmacovigilance process
  • Clinical studies
    • Identifying patients at risk for DILI (AIH, viral liver disease, alcoholic liver disease, and NAFLD)
    • Host factors that contribute to assessing DILI risk
    • DILI risk in specific populations, such as diabetes mellitus, cancer, or preexisting liver diseases
    • Management of clinical DILI (e.g., how to treat DILI patients)
    • Hepatotoxicity related to herbs and dietary supplements

Articles

  • Special Issue
  • - Volume 2017
  • - Article ID 2461694
  • - Editorial

Drug-Induced Liver Injury

Eileen E. N. Almario | Jürgen Borlak | ... | Minjun Chen
  • Special Issue
  • - Volume 2016
  • - Article ID 7150391
  • - Review Article

Research Advances on Hepatotoxicity of Herbal Medicines in China

Changxiao Liu | Huirong Fan | ... | Xiaohe Xiao
  • Special Issue
  • - Volume 2016
  • - Article ID 1829148
  • - Review Article

Advances in Engineered Liver Models for Investigating Drug-Induced Liver Injury

Christine Lin | Salman R. Khetani
  • Special Issue
  • - Volume 2016
  • - Article ID 9737920
  • - Review Article

Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation Plans

Franck A. Atienzar | Eric A. Blomme | ... | Donna M. Dambach
  • Special Issue
  • - Volume 2016
  • - Article ID 1473578
  • - Research Article

Expression of miRNA-122 Induced by Liver Toxicants in Zebrafish

Hyun-Sik Nam | Kyu-Seok Hwang | ... | Cheol-Hee Kim
  • Special Issue
  • - Volume 2016
  • - Article ID 8758460
  • - Research Article

Ultrastructural Mapping of the Zebrafish Gastrointestinal System as a Basis for Experimental Drug Studies

Delfine Cheng | Gerald J. Shami | ... | Filip Braet
  • Special Issue
  • - Volume 2016
  • - Article ID 5823271
  • - Research Article

Oxidative Stress and Liver Morphology in Experimental Cyclosporine A-Induced Hepatotoxicity

Agnieszka Korolczuk | Kinga Caban | ... | Joanna Irla-Miduch
  • Special Issue
  • - Volume 2016
  • - Article ID 9576503
  • - Research Article

Study of Valproic Acid-Enhanced Hepatocyte Steatosis

Renin Chang | Mei-Chia Chou | ... | Chih-Hsien Chiu
BioMed Research International
 Journal metrics
Acceptance rate31%
Submission to final decision67 days
Acceptance to publication30 days
CiteScore3.600
Impact Factor2.276
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.